Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. OCC
OCC logo

OCC Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Optical Cable Corp (OCC) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
9.110
1 Day change
0.55%
52 Week Range
11.500
Analysis Updated At
2026/04/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Optical Cable Corp (OCC) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the technical indicators show some bullish signals, the lack of significant trading trends, poor financial performance in the latest quarter, and absence of positive news or catalysts make it prudent to hold off on investing in this stock for now.

Technical Analysis

The technical indicators show a mixed picture. The MACD is positive and contracting, indicating a slight bullish momentum. The RSI is neutral at 59.821, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock price is close to its pivot level of 8.713, with resistance levels at 10.151 and 11.039, and support levels at 7.274 and 6.386.

Positive Catalysts

  • Bullish moving averages and a slight increase in the regular market price (+0.55%).

Neutral/Negative Catalysts

  • No significant trading trends from hedge funds or insiders. Financial performance is weak, with a significant drop in net income (-64.10% YoY) and EPS (-64.29% YoY). No recent news or positive sentiment to drive the stock higher.

Financial Performance

In Q1 2026, revenue increased by 4.37% YoY to $16,430,955. However, net income dropped significantly by 64.10% YoY to -$397,529, and EPS fell by 64.29% YoY to -0.05. Gross margin improved to 32.56%, up 11.28% YoY, but overall profitability remains a concern.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes available.

Wall Street analysts forecast OCC stock price to rise
Analyst Rating
0
Wall Street analysts forecast OCC stock price to rise
Buy
Hold
Sell
0
Current: 9.060
sliders
Low
0
Averages
0
High
0
0
Current: 9.060
sliders
Low
0
Averages
0
High
0
Canaccord
Shane Storey
Speculative Buy
initiated
$1.33
AI Analysis
2025-12-17
Reason
Canaccord
Shane Storey
Price Target
$1.33
AI Analysis
2025-12-17
initiated
Speculative Buy
Reason
Canaccord analyst Shane Storey initiated coverage of Orthocell with a Speculative Buy rating and A$1.33 price target. The regenerative medicine company is commercializing novel collagen-based devices for peripheral nerve repair, including its flagship product, Remplir, the analyst tells investors. Recently achieved key global clearances, including FDA 510(k) clearance in April, position the company "at the start of a multi-year commercial expansion," the analyst added.

People Also Watch